AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 311 min read$SOPH

Xu Zhenyu sold $89K of SOPH

Xu Zhenyu (Chief Scientific Officer) sold 10,000 shares of SOPHiA GENETICS SA (SOPH) at $8.91 on 2026-08-27 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Xu Zhenyu
Published Aug 31, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosed sale is modest and pre‑arranged, offering limited actionable insight.

02

Market read

Minor insider sale with negligible market impact.

03

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 2/10Novelty 3/10Timing: filing date 2026‑08‑31

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

Chief Scientific Officer Xu Zhenyu sold 10,000 SOPH shares for $89,096 under a 10b5‑1 plan.

Expected impact

Minimal short‑term pressure; unlikely to move price materially.

Evidence & confidence

Sale represents ~0.18% of post‑transaction holdings and is pre‑arranged, reducing informational value.

Market effects

Sector

No immediate sector impact; SOPHiA operates in genomics data analytics.

Regional

Limited to European biotech investors.

Global

Low global relevance.

Counterpoint

What could challenge this read

Sale could be routine liquidity need, not a negative signal.

Key entities

  • Company
    SOPHiA GENETICS SA

    Swiss genomics data‑analytics firm listed on NASDAQ as SOPH.

  • Insider
    Xu Zhenyu

    Chief Scientific Officer of SOPHiA GENETICS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min